William Blair has recently reduced Incyte Corp (INCY) stock to Mkt Perform rating, as announced on March 18, 2025, according to Finviz. Earlier, on March 18, 2025, Guggenheim had reduced the stock from a Buy to Neutral. UBS also initiated Neutral rating with a price target of $77. Additionally, BofA Securities raised Buy rating on October 29, 2024, with a target price of $90. Wolfe Research analysts, in their report published on October 1, 2024, also initiated Outperform rating and set a price target of $84 for Incyte Corp’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Incyte Corp (INCY) Stock Trading Recap
On Monday, Incyte Corp (INCY) stock saw a modest uptick, ending the day at $59.22 which represents a slight increase of $2.35 or 4.13% from the prior close of $56.87. The stock opened at $57.29 and touched a low of $57.12 during the day, reaching a high of $59.3. The volume of shares traded was 2.09 million exceeding the average volume of 1.93 million.
Sponsored
INCY Stock Performance and Moving Averages
In recent trading, Incyte Corp (INCY) stock price has shown some volatility, fluctuating -1.77% over the last five trades and -12.73% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -9.41%, and it has plunged by -18.17% in the previous three months. Currently, INCY is trading at -1.66%, -11.09%, and -12.53% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, INCY, a Healthcare sector stock, is trading -29.46% below its 52-week high but remains 17.62% above its 52-week low. The Average True Range (ATR) (14 days) of 2.80 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Incyte Corp’s Profitability and Valuation Ratios
Incyte Corp’s profitability metrics reveal financial health. The company currently boasts an operating margin of 1.89% and a profit margin of 0.77%, with a gross margin of -9.41%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Incyte Corp’s market capitalization stands at $11.46 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 218.36, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 9.16. Additionally, the Price-to-Sales Ratio is 2.70, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.32, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.56% of Incyte Corp (INCY)’s shares, while financial institutions hold 95.68%.
Notable insider trades include Flannelly Barry P, EVP & General Manager US at Incyte Corp (INCY), who sold 19,807 shares on Mar 14 ’25, at $67.69 each, totaling $1.34 million. On Feb 26 ’25, Denton Sheila A., EVP & General Counsel, sold 14,069 shares for $74.07 each, amounting to $1.04 million. Additionally, on Jan 21 ’25, Stein Steven H sold 12,352 shares at $72.69 each, generating $0.90 million.
